title: Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?
abstract: OBJECTIVE
  To determine if any preoperative or intraoperative factors can reliably predict malignancy in patients with Hürthle cell neoplasms.
  
  
  BACKGROUND
  Most experienced surgeons recommend total thyroidectomy for Hürthle cell carcinomas and reserve thyroid lobectomy for Hürthle cell adenomas. However, delineation between Hürthle cell adenoma versus carcinoma often cannot reliably be made either before or during surgery.
  
  
  METHODS
  Medical records from 57 consecutive patients who underwent thyroid resections for Hürthle cell neoplasms between October 1984 and April 1995 at The Johns Hopkins Hospital were analyzed to determine if any factors were predictive of malignancy.
  
  
  RESULTS
  Of the 57 patients with Hürthle cell neoplasms, 37 had adenomas and 20 had carcinomas, resulting in a 35% prevalence of malignancy. Patients with adenomas did not differ from those with carcinoma with respect to age, sex, or history of head and neck irradiation. However, patients with Hürthle cell carcinomas had significantly larger tumors (4.0 +/- 0.4 cm vs. 2.4 +/- 0.2 cm, p < 0.005). Furthermore, although the incidence of malignancy was only 17% for tumors 1 cm or less and 23% for tumors 1 to 4 cm, tumors 4 cm or greater were malignant 65% of the time (p < 0.05). Both fine-needle aspiration and intraoperative frozen section analysis had low sensitivities in the detection of cancer (16% and 23%, respectively). With up to 9 years of follow-up, there has been no tumor-related mortality.
  
  
  CONCLUSIONS
  These data demonstrate that the size of a Hürthle cell neoplasm is predictive of malignancy. Therefore, at the time of initial exploration for large Hürthle cell neoplasms (>4 cm), definitive resection involving both thyroid lobes should be considered because of the higher probability of malignancy.
authors.affiliation: Department of Surgery, The Johns Hopkins Medical Institutions and The Johns Hopkins Thyroid Tumor Center, Baltimore, Maryland, USA.
authors.forename: H
authors.initials: H
authors.lastname: Chen
authors.forename: T L
authors.initials: TL
authors.lastname: Nicol
authors.forename: M A
authors.initials: MA
authors.lastname: Zeiger
authors.forename: W C
authors.initials: WC
authors.lastname: Dooley
authors.forename: P W
authors.initials: PW
authors.lastname: Ladenson
authors.forename: D S
authors.initials: DS
authors.lastname: Cooper
authors.forename: M
authors.initials: M
authors.lastname: Ringel
authors.forename: S
authors.initials: S
authors.lastname: Parkerson
authors.forename: M
authors.initials: M
authors.lastname: Allo
authors.forename: R
authors.initials: R
authors.lastname: Udelsman
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000601:surgery; D000236:Adenoma / Q000473:pathology / Q000601:surgery; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D013964:Thyroid Neoplasms / Q000473:pathology* / Q000601:surgery; D013965:Thyroidectomy